Vomiting in children and adolescents receiving intravenous pegaspargase: a retrospective study.

IF 1.2 4区医学 Q4 HEMATOLOGY

Pediatric Hematology and Oncology Pub Date : 2024-08-01 Epub Date: 2024-03-07 DOI:10.1080/08880018.2024.2311886

Jamie M Brown, Sherry Mathew, Maria Luisa Sulis, L Lee Dupuis, Jennifer Thackray

引用次数: 0

Abstract

Due to an evidence gap, the emetogenicity of intravenous (IV) pegaspargase was unable to be included in the clinical practice guideline classifying chemotherapy emetogenicity in pediatric patients. This single-center, retrospective chart review describes the proportion of pediatric patients who did not vomit during the acute phase (complete response; CR) after receiving IV pegaspargase and provides an emetogenicity classification using a preexisting framework. Of 44 patients who received IV pegaspargase between 2011 and 2020, 13 received a serotonin receptor antagonist plus dexamethasone or palonosetron alone and all experienced a CR. We, therefore, recommend classifying IV pegaspargase as moderately emetogenic.

查看原文本刊更多论文

静脉注射培加司琼酶的儿童和青少年的呕吐：一项回顾性研究。

由于存在证据缺口，静脉注射（IV）培果巴糖酶的致吐性未能纳入儿科患者化疗致吐性分类临床实践指南。这篇单中心回顾性病历回顾描述了接受静脉注射培加司的、在急性期（完全应答；CR）没有呕吐的儿科患者比例，并利用已有的框架提供了致吐性分类。在 2011 年至 2020 年期间接受静脉注射培加司琼的 44 名患者中，有 13 名患者接受了血清素受体拮抗剂加地塞米松或帕洛诺司琼单药治疗，所有患者都出现了 CR。因此，我们建议将静脉注射培加司琼列为中度致吐药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Hematology and Oncology 医学-小儿科

CiteScore

2.60

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.